Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Klaus H. Metzeler, Eric S. Winer, Uwe Platzbecker, Amit Verma, Daniel J. DeAngelo, Stefano R. Tarantolo, David A. Sallman, James Dugan, Stefanie Gröpper, Katharina S. Goetze, Chia-Cheng Li, Wanying Zhao, Maureen Lane, Reinhard von Roemeling, Samantha Carlisle, Anne Weigert, Matthias Böhme, Anne Sophie Kubasch, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 9048–9049.

https://doi.org/10.1182/blood-2022-167477

Published: 2022

Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2742.

https://doi.org/10.1182/blood-2021-148385

Published: 2021

Journal Articles

A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Guillermo Garcia-Manero, MD, Uwe Platzbecker, Stefano R. Tarantolo, MD, Stefanie Gropper, Chetasi Talati, MD, Katharina S. Götze, James Dugan, MD, Eric S. Winer, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-140889

Published: 2020

Journal Articles

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Tara K. Gregory, MD, Suman Kambhampati, MD, Bertrand M. Anz, III, MD, Stefano R. Tarantolo, MD, Anthony A. Meluch, MD, Jeffrey V. Matous, MD

Blood (2019) 134 (Supplement_1): 603.

https://doi.org/10.1182/blood-2019-130277

Published: 2019

Journal Articles

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma

Ajay K. Gopal, MD, Stefano R Tarantolo, Naresh Bellam, MD, MPH, Tatyana Feldman, MD, Anthony R Mato, MD, Damian J Green, MD, Melissa Griffin, Scott Stromatt, MD, Andre Goy, MD

Blood (2012) 120 (21): 3678.

https://doi.org/10.1182/blood.V120.21.3678.3678

Published: 2012

Journal Articles

Factors Affecting the Development of Atrial Fibrillation and Atrial Flutter (AF) Following Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT).

Mary Lee H. Villanueva, MD, Fausto R. Loberiza, MD, MS, James O. Armitage, MD, Robert G. Bociek, MD, Apar Kishor Ganti, MD, James C. Lynch, PhD, Farhan Majeed, MD, Stefano R. Tarantolo, MD, Jo Torrey, RN, BSN, Julie M. Vose, MD, Philip J. Bierman, MD

Blood (2005) 106 (11): 1754.

https://doi.org/10.1182/blood.V106.11.1754.1754

Published: 2005

Journal Articles

Vincristine-Laden Platelets Can Improve Platelet Counts in Patients with Refractory Thrombocytopenia.

Apar Kishor Ganti, MD, Stefano R. Tarantolo, MD, Lynette M. Smith, MS, Anne Kessinger, MD, James D. Landmark, MD

Blood (2004) 104 (11): 3640.

https://doi.org/10.1182/blood.V104.11.3640.3640

Published: 2004

Journal Articles

Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics

Shantaram S. Joshi, James C. Lynch, Steve Z. Pavletic, Stefano R. Tarantolo, Samuel J. Pirruccello, Anne Kessinger, Michael R. Bishop

Blood (2001) 98 (6): 1963–1970.

https://doi.org/10.1182/blood.V98.6.1963

Published: 2001

Journal Articles

A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation

Michael R. Bishop, Stefano R. Tarantolo, Robert B. Geller, James C. Lynch, Philip J. Bierman, Z. Steven Pavletic, Julie M. Vose, Susan Kruse, Suzanne P. Dix, Mary E. Morris, James O. Armitage, Anne Kessinger

Blood (2000) 96 (1): 80–85.

https://doi.org/10.1182/blood.V96.1.80

Published: 2000

NARROW

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma

Factors Affecting the Development of Atrial Fibrillation and Atrial Flutter (AF) Following Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT).

Vincristine-Laden Platelets Can Improve Platelet Counts in Patients with Refractory Thrombocytopenia.

Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics

A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only